VYGR Voyager Therapeutics Inc.

Voyager Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Participate in Upcoming Investor Conference

Voyager Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Participate in Upcoming Investor Conference

CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, will report fourth quarter and full year 2020 financial results after market close on Thursday, February 25, 2021. Subsequently, at 4:30 p.m. EST, the Company will host a live conference call and webcast to discuss its financial results and provide a corporate update.

The conference call may be accessed by dialing (877) 851-3834 for domestic callers, or +1 (631) 291-4595 for international callers. Please reference conference ID number 3688928 to join the call. The conference call will be webcast live from the Investors & Media section of Voyager’s website at  and will be archived there following the call for 90 days.

Additionally, the company will participate in a panel discussion at the Cowen 41st Annual Health Care Conference on Monday, March 1, 2021 at 11:40 a.m. EST.

The webcast session may be accessed from the Investors & Media section of Voyager’s website at . Replays of the webcast will be archived on the Company's website for at least 30 days.

About Voyager Therapeutics

Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques. Voyager’s wholly owned and partnered pipeline focuses on severe neurological diseases for which effective new therapies are needed, including Parkinson’s disease, Huntington’s disease, Friedreich’s ataxia, and other severe neurological diseases. For more information on Voyager Therapeutics, please visit the company’s website at or follow on Twitter and .

Investors:

Media:

Sheryl Seapy

W2Opure

949-903-4750



EN
18/02/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Voyager Therapeutics Inc.

 PRESS RELEASE

Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operat...

Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results - Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 -  - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies to enter clinic H2 2026 - - Advancing Voyager NeuroShuttle™: murine study using anti-amyloid antibody supports sustained brain exposure profile - - Ended 2025 with cash position of $202 million, expected to maintain runway into 2028 - LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics...

David Nierengarten ... (+8)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Laura Chico
  • Martin Fan
  • Robert Driscoll
  • Thomas Yip
  • Yun Zhong

ResearchPool Subscriptions

Get the most out of your insights

Get in touch